Cardiovascular Diabetology (Jul 2011)

Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men

  • Bjerre Mette,
  • Bax Jeroen J,
  • Smit Jan WA,
  • Romijn Johannes A,
  • Lamb Hildo J,
  • de Roos Albert,
  • Lammertsma Adriaan A,
  • Lubberink Mark,
  • van Duinkerken Eelco,
  • Heymans Martijn W,
  • van der Meer Rutger W,
  • Rijzewijk Luuk J,
  • Chen Weena JY,
  • Frystyk Jan,
  • Flyvbjerg Allan,
  • Diamant Michaela

DOI
https://doi.org/10.1186/1475-2840-10-67
Journal volume & issue
Vol. 10, no. 1
p. 67

Abstract

Read online

Abstract Background Osteoprotegerin (OPG), a soluble member of the tumor necrosis factor receptor superfamily, is linked to cardiovascular disease. Negative associations exist between circulating OPG and cardiac function. The adipocytokine adiponectin (ADPN) is downregulated in type 2 diabetes mellitus (T2DM) and coronary artery disease and shows an inverse correlation with insulin sensitivity and cardiovascular disease risk. We assessed the relationship of plasma OPG and ADPN and arterial function, cardiac function and myocardial glucose metabolism in T2DM. Methods We included 78 asymptomatic men with uncomplicated, well-controlled T2DM, without inducible ischemia, assessed by dobutamine-stress echocardiography, and 14 age-matched controls. Cardiac function was measured by magnetic resonance imaging, myocardial glucose metabolism (MMRglu) by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography. OPG and ADPN levels were measured in plasma. Results T2DM patients vs. controls showed lower aortic distensibility, left ventricular (LV) volumes, impaired LV diastolic function and MMRglu (all P P Conclusions OPG was inversely associated with aortic distensibility, LV volumes and LV diastolic function, while ADPN was positively associated with MMRglu. These findings indicate that in asymptomatic men with uncomplicated T2DM, OPG and ADPN may be markers of underlying mechanisms linking the diabetic state to cardiac abnormalities. Trial registration Current Controlled Trials ISRCTN53177482

Keywords